Comparison of the most recent guidelines for hyperglycemia management in patients with type 2 diabetes mellitus

Czech version

Authors: Zbynek Schroner ¹; Vladimír Uličiansky ²
Authors‘ workplace: SchronerMED s. r. o, Košice ¹; Via medica s. r. o., Košice ²
Published in: Diab Obez 2020; 20(39): 7-11
Category: Guidelines

Overview

New guidelines ADA/EASD 2018, also update 2019 for the management of hyperglycemia in type 2 diabetes emphasize as a second choice after metformin therapy, in patients with cardiovascular (CV) disease or high CV risk, chronic kidney disease, importance mainly of SGLT2 inhibitors and GLP-1 receptor agonists. These two classes have not only antidiabetic effects but also cardioprotective nad renoprotective benefits. 2019 ESC/EASD guidelines on diabetes, pre-diabetes, and CV diseases in patients with CV disease or high/very high CV risk recommend as first -line therapy not metformin but SGLT2 inhibitor or GLP-1 receptor agonist. Individualised approach is always important.

Keywords:

type 2 diabetes mellitus – new guidelines ADA/EASD and ESC/EASD

Sources

Davies MJ, D Alessio DA, Fradkin J et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2018; 61(12): 2461–2498. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–018–4729–5>. Erratum in Correction to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). [Diabetologia 2019].
Davies MJ, D Alessio DA, Fradkin J, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 41(12): 2669–2701. Dostupné z DOI: <http://dx.doi.org/10.2337/dci18–0033>.
Buse JB, Wexler D, Tsapas A et al. 2019 update to: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2020; 43(2): 487–493. Dostupné z DOI: <http://dx.doi.org/10.2337/dci19–0066>.
Cosentino F, Grant PJ, Aboyans V et al. [ESC Scientific Document Group]. 2019 ESC Guidelines on diabetes, pre-diabetes and cardiovascular diseases developed in collaboration with EASD. Eur Heart J 2020; 41(2): 255–323. Dostupné z DOI: <https://doi: 10.1093/eurheartj/ehz486>.
Martinka M, Uličiansky V, Mokáň M et al. Konsenzuálne terapeutické odporúčanie Slovenskej diabetologickej spoločnosti pre diabetes mellitus 2. typu. Forum Diab 2018; 7(1): 47–68.